Bonus BioGroup Income Statement

Financials in millions ILS. Fiscal year is January - December.

Millions ILS. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Selling, General & Admin	10.59	10.23	11.18	15.74	43.94	8.09	Upgrade
Research & Development	14.06	17.61	18.61	21.31	20.79	11.36	Upgrade
Operating Expenses	24.65	27.84	29.79	37.05	64.74	19.44	Upgrade
Operating Income	-24.65	-27.84	-29.79	-37.05	-64.74	-19.44	Upgrade
Interest Expense	-0.82	-0.78	-0.85	-0.89	-0.57	-0.41	Upgrade
Interest & Investment Income	-	0.83	2.14	7.28	0.16	-	Upgrade
Currency Exchange Gain (Loss)	-	-	-	-	-3.93	0.05	Upgrade
Other Non Operating Income (Expenses)	-0.04	-0.04	-0.03	-8.04	-21.01	-2.22	Upgrade
EBT Excluding Unusual Items	-25.52	-27.83	-28.53	-38.7	-90.08	-22.02	Upgrade
Pretax Income	-25.52	-27.83	-28.53	-38.7	-90.08	-22.02	Upgrade
Net Income	-25.52	-27.83	-28.53	-38.7	-90.08	-22.02	Upgrade
Net Income to Common	-25.52	-27.83	-28.53	-38.7	-90.08	-22.02	Upgrade
Shares Outstanding (Basic)	-	1,168	1,168	1,168	1,154	999	Upgrade
Shares Outstanding (Diluted)	-	1,168	1,168	1,168	1,154	999	Upgrade
Shares Change (YoY)	-	-	-	1.20%	15.52%	18.72%	Upgrade
EPS (Basic)	-	-0.02	-0.02	-0.03	-0.08	-0.02	Upgrade
EPS (Diluted)	-	-0.02	-0.02	-0.03	-0.08	-0.02	Upgrade
Free Cash Flow	-18.38	-21.72	-27.22	-35.2	-45.65	-16	Upgrade
Free Cash Flow Per Share	-	-0.02	-0.02	-0.03	-0.04	-0.02	Upgrade
EBITDA	-23.04	-26.2	-28.14	-34.38	-63.26	-18.38	Upgrade
D&A For EBITDA	1.62	1.63	1.65	2.66	1.48	1.07	Upgrade
EBIT	-24.65	-27.84	-29.79	-37.05	-64.74	-19.44	Upgrade

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.